CSI Market
Sign In | Register

Skye Bioscience Inc (SKYE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SKYE Annual Cash Flow →
Reviewing cash flow figures over time highlights how Skye Bioscience Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-12.51
Depreciation & amortization0.17
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Other Assets0.01
Share-based Compensation1.50
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Deposits And Other Assets-
Increase Decrease In Accrued License And Patent Reimbursement Fees-
Gain Loss On Conversion Right Preferred Stock-
Fixed Assets Provided To University In Lieu Of Cash-
Fair Value Of Warrant Liability Excess Of Proceeds-
Fair Value Adjustment Of Derivative Liabilities-
Increase Decrease In Prepaid Expenses Due From Related Parties-
Increase Decrease In Other Current Assets From Related Party-
Increase Decrease In Other Assets Due From Related Parties-
Finance Charge From Sciences Warrant Repricing-
Induced Conversion Of Convertible Debt Expense-
Write Down Of Vendor Deposits-
Loss Contingency Accrual Provision-
Operating Lease Right Of Use Asset Amortization Expense0.17
Increase Decrease In Operating Lease Liability-0.21
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Employee Related Liabilities-1.04
Increase (Decrease) in Accounts Payable, Trade1.90
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.40
Other Working Capital1.84
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-8.56
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Short-term Investments, Total10.90
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment For Asset Acquisitions-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Proceeds from Sale of Other Assets, Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities10.90
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.07
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.88
Issuance Of Notes Receivable-
Payments Received From Notes Receivable-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Series B Preferred Stock Issuance-
Common Stock Issued For Services-
Proceeds From Emerald Financing Net Of Issuance Costs-
Proceeds From Convertible Multi Draw Credit Agreement-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents5.88
Proceeds From Pre Funded Warrant Exercises-
Repayment Of Convertible Multi Draw Credit Agreement-
Proceeds From Sale Of Common Stock And Warrants Net Of Issuance Costs-
Capital Expenditures Incurred But Not Yet Paid-
Financing Of Insurance Premium-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.07
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.56
Total Cash Flow2.27
4 historic quarters locked

Sign in to unlock the full Skye Bioscience Inc cash flow history.

Sign In Create Free Account

About Skye Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-056968

Figures are derived from filed reports and may be restated. Historical data is subject to revision.